Borrower record · Q2 2026
LGM PHARMA
As filed by Capital Southwest Corporation · period end 30 June 2026No sector — one filer, nothing to corroborate
Capital Southwest Corporation is the only BDC lending to LGM PHARMA: $37.9m across five positions at Q2 2026, marked at 107.7 cents. All of it comes due inside two years — the last tranche in November 2026.
- Filed fair value
- $37.9m
- 5 funded positions
- Aggregate mark
- 107.7c
- covers 83% of positions with a filed cost
- Median spread
- 850bp
- over SOFR, 4 tranches
- Maturities to
- 2026
- one date, 20 November 2026
- Periods on record
- 5
- Q2 2025 → Q2 2026
How this total is counted
- Every figure above is the sum of 5 funded positions filed by Capital Southwest Corporation, each one cited below.
- Counted from the Q2 2026 filings imported for this build, the latest of them filed 20 August 2026. A schedule filed after that date is not in these figures and will appear when the property is rebuilt.
- 1 filed position carries no positive fair value — unfunded or written off — and is outside every figure above.
Pricing as filed
4 floating tranches · SOFRBar length is the number of tranches filed at that spread. The accented row holds the median tranche.
850bp weighted by fair value, across the same 4 tranches.
4 tranches carry an index floor of 1%.
Capital structure
All 5 funded positions carry a filed seniority.
Rate structure
Floating, on all 4 positions whose interest type a filer disclosed.
1 of 5 funded positions carries no filed interest type.
Maturity profile
4 of 5 funded positions dated0.4 years to maturity, weighted by fair value across the 4 dated positions.
Filed over time
5 periods · aggregate onlyFiled fair value
Aggregate marknot to zero
Q2 2025, Q3 2025, Q4 2025, Q1 2026, Q2 2026 — every filer reporting the borrower at each period, aggregated. No lender is separated out at any period.
Credit flags
The filer reports no position on non-accrual, and no filed tranche pays in kind.
Not in the filings
- No sector, and there cannot be one: the test needs two filers to agree and only one filed a label.
- No maturity on 1 of 5 funded positions. Undated is left undated, not assumed.
- No filed cost on 17% of positions, which the aggregate mark therefore excludes.
Sign up for free
Tell me when this changes.
One lender reports LGM PHARMA today. We will email you when a second one does, when Capital Southwest Corporation's mark moves, or when the position leaves the schedule.
- A second BDC reports this borrower
- The filed mark moves by more than two cents
- A position goes on non-accrual or starts paying in kind
- The borrower drops out of the schedule entirely
Every filing behind this page
1 filer · Q2 2026| Filer | CIK | Form | Period | Filed | Accession |
|---|---|---|---|---|---|
| Capital Southwest Corporation (CSWC) | 0000017313 | 10-Q | 2026-06-30 | 2026-08-03 | 0000017313-26-000095 |
Related borrowers
Same lender